The Miriam Hospital clinical trials unit offers the newest treatments for HIV and hepatitis C (HCV) infections. The experienced research staff consists of physicians, nurses, a data manager, a regulatory assistant and laboratory personnel.
We conduct trials offered through the AIDS Clinical Trials Group (ACTG) network, funded by the National Institutes of Health, in association with the Partners/Harvard AIDS Clinical Trials Unit. The priority of ACTG studies is to evaluate new strategies for treating HIV infection and preventing HIV complications, and to evaluate new treatments for hepatitis C.
Other studies offered through our clinical trials unit include pharmaceutical studies to treat hepatitis C, prevent C. difficile infection, and test new methods of diagnosing HIV infection.
For more information about clinical trials, please visit www.clinicaltrials.gov or contact us directly:
To inquire about any of our studies call 401-793-4317 or email IDResearch@brownhealth.org.
This study designed to evaluate the safety and efficacy of investigational agents, both infused and non-infused, for the treatment of symptomatic non-hospitalized adults with COVID-19.
Key Requirements
For more information, please visit: riseabovecovid.org or call 877-345-8813
This study designed to examine the effects of alcohol on the immune system and the brain.
Key Requirements
This study designed to examine a new way to help smokers with HIV quit smoking successfully by starting nicotine patch prior to the quit date.
Key Requirements
